Stay updated on Pembrolizumab + Ibrutinib in Stage III-IV Melanoma Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab + Ibrutinib in Stage III-IV Melanoma Clinical Trial page.

Latest updates to the Pembrolizumab + Ibrutinib in Stage III-IV Melanoma Clinical Trial page
- Check7 days agoChange DetectedPage revision updated from v3.4.0 to v3.4.1. No changes to study content or eligibility criteria are indicated.SummaryDifference0.1%

- Check14 days agoChange DetectedAdded a 'Show glossary' option, introduced the label 'Last Update Submitted that Met QC Criteria' (changing from 'Last Update Submitted that met QC Criteria'), and adjusted capitalization for 'No FEAR Act Data'. The site revision was updated from v3.3.4 to v3.4.0; To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%

- Check21 days agoChange DetectedAdministrative updates to the study page include new 2026 update dates and the removal of an older regulatory note; these are updates to page metadata rather than the study content. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.3%

- Check28 days agoChange DetectedMinor update: revision label changed from v3.3.3 to v3.3.4; no study content or functionality was changed.SummaryDifference0.1%

- Check49 days agoChange DetectedAdds Minnesota as a Location under the Locations section (revision v3.3.3) and removes the HHS Vulnerability Disclosure and Minnesota Locations entries (revision v3.3.2).SummaryDifference0.2%

- Check78 days agoChange DetectedPublications section wording updated to indicate that publications are automatically filled from PubMed, and the revision tag changed from v3.2.0 to v3.3.2. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

Stay in the know with updates to Pembrolizumab + Ibrutinib in Stage III-IV Melanoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab + Ibrutinib in Stage III-IV Melanoma Clinical Trial page.